Dongwha Pharm said on the 22nd that its cold medicine "PANCOLD S" ranked No. 1 in sales in the cold medicine market for the third consecutive year.
IQVIA analyzed domestic cold medicine sales over the past year (Q4 2024–Q3 2025) and found that PANCOLD S posted 38 billion won in sales. That amounts to a market share of about 29% in a cold medicine market worth about 132.3 billion won.
PANCOLD S first rose to No. 1 in sales in IQVIA's third-quarter 2023 survey and has held the top spot for three consecutive years.
Launched in 1968, "PANCOLD" is a cold medicine that contains acetaminophen, which has antipyretic and analgesic effects. PANCOLD currently consists of four product lines: ▲ the pharmacy-sold adult cold medicine "PANCOLD S" ▲ the children's "PANCOLD I-COLD Syrup" ▲ the convenience-store over-the-counter essential medicine "PANCOLD A" ▲ and the tea-type cold medicine launched this year, "PANCOLD H."
By Dongwha Pharm's own tally, the total sales of the PANCOLD product line reached 57.3 billion won last year.
A Dongwha Pharm official said, "PANCOLD S is a representative cold medicine that continues to be loved even more than 50 years after its launch," adding, "We will continue to enhance quality and safety and lead the cold medicine market."